Innovative approaches to bipolar disorder and its treatment

Annals of the New York Academy of Sciences

Volumn 1366, Issue 1, 2016, Pages 76-89

  Harrison, Paul J ^a,b   Cipriani, Andrea ^a,b   Harmer, Catherine J ^a,b   Nobre, Anna C ^a,b,c   Saunders, Kate ^a,b   Goodwin, Guy M ^a,b   Geddes, John R ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Bipolar disorder; Clinical; Genetics; Mood; Therapy

Indexed keywords

CALCIUM CHANNEL; LITHIUM; MOOD STABILIZER; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG COST; DRUG EFFECT; DRUG SAFETY; EVIDENCE BASED PRACTICE; EXPERIMENTAL MEDICINE; EXPERIMENTAL THERAPY; GENETICS; HUMAN; MENTAL INSTABILITY; NONHUMAN; PATHOPHYSIOLOGY; TREATMENT RESPONSE; ANIMAL; GENOME-WIDE ASSOCIATION STUDY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; GENOME-WIDE ASSOCIATION STUDY; HUMANS; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 84969190214     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13048     Document Type: Article

References (164)

1. Phillips, M.L. & D.J. Kupfer . 2013. Bipolar disorder diagnosis: challenges and future directions. Lancet 381: 1663-1671.
2. Bourne, C., O. Aydemir, V. Balanza-Martinez, et al. 2013. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr. Scand. 128: 149-162.
3. Ostergaard, S.D., A. Bertelsen, J. Nielsen, et al. 2013. The association between psychotic mania, psychotic depression and mixed affective episodes among 14, 529 patients with bipolar disorder. J. Affect. Disord. 147: 44-50.
4. Vieta, E. & M. Valentí . 2013. Mixed states in DSM-5: implications for clinical care, education, and research. J. Affect. Disord. 148: 28-36.
5. Broome, M., K.E.A. Saunders, P.J. Harrison & S. Marwaha . 2015. Mood instability. Br. J. Psychiatry 207: 283-285.
6. Faedda, G.L., C. Marangoni, G. Serra, et al. 2015. Precursors of bipolar disorders: a systematic literature review of prospective studies. J. Clin. Psychiatry 76: 614-624.
7. Tsitsipa, E. & K. Fountoulakis . 2015. The neurocognitive functioning in bipolar disorder: a systematic review of data. Ann. Gen. Psychiatry 14: 42.
8. Craddock, N. & M.J. Owen . 2010. The Kraepelinian dichotomy-going, going... but still not gone. Br. J. Psychiatry 196: 92-95.
9. Miller, S., B. Dell'Osso & T.A. Ketter . 2014. The prevalence and burden of bipolar depression. J. Affect. Disord. 169(Suppl. 1): S3-S11.
10. Di Florio, A., N. Craddock & M. van den Bree . 2014. Alcohol misuse in bipolar disorder. A systematic review and meta-analysis of comorbidity rates. Eur. Psychiatry 29: 117-124.
11. Merikangas, K.R., H.S. Akiskal, J. Angst, et al. 2007. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 64: 543-552.
12. Parker, G., S. McCraw, D. Hadzi-Pavlovic & K. Fletcher . 2013. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J. Affect. Disord. 149: 46-55.
13. Pompili, M., X. Gonda, G. Serafini, et al. 2013. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 15: 457-490.
14. Hayes, J.F., J. Miles, K. Walters, et al. 2015. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr. Scand. 131: 417-425.
15. Chesney, E., G.M. Goodwin & S. Fazel . 2014. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 13: 153-160.
16. Kessing, L.V., E. Vradi & P.K. Andersen . 2015. Life expectancy in bipolar disorder. Bipolar Disord. 17: 543-548.
17. Cipriani, A., J.R. Geddes, J. Higgins & G. Salanti . 2013. Conceptual and technical challenges in network meta-analysis. Ann. Intern. Med. 159: 130-137.
18. Mavridis, D., M. Giannatsi, A. Cipriani & G. Salanti . 2015. A primer on network meta-analysis with emphasis on mental health. Evid. Based Ment. Health 18: 40-46.
19. Geddes, J.R. & D.J. Miklowitz . 2013. Treatment of bipolar disorder. Lancet 381: 1672-1682.
20. National Institute for Health and Clinical Excellence. 2014. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. NICE clinical guideline 185. http://guidance.nice.org.uk/CG185. Accessed March 23, 2016.
21. Malhi, G.S., D. Bassett, P. Boyce, et al. 2015. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust. N.Z. J. Psychiatry 49: 1087-1206.
22. Goodwin, G.M. & Consensus Group of the British Association for Psychopharmacology. 2009. Evidence-based guidelines for treating bipolar disorder: revised third edition-recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 23: 346-388.
23. Cipriani, A., C. Barbui, G. Salanti, et al. 2011. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378: 1306-1315.
24. Yildiz, A., M. Nikodem, E. Vieta, et al. 2015. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol. Med. 45: 299-317.
25. Frye, M.A., M.L. Prieto, W.V. Bobo, et al. 2014. Current landscape, unmet needs, and future directions for treatment of bipolar depression. J. Affect. Disord. 169(Suppl. 1): S17-S23.
26. Kendall, T., R. Morriss, E. Mayo-Wilson, E. Marcus ; Guideline Development Group of the National Institute for Health and Care Excellence. 2014. Assessment and management of bipolar disorder: summary of updated NICE guidance. Br. Med. J. 349: g5673.
27. Taylor, D.M., V. Cornelius, L. Smith & A.H. Young . 2014. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr. Scand. 130: 452-469.
28. Durgam, S., W. Earley, A. Lipschitz, et al. 2016. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am. J. Psychiatry 173: 271-281.
29. Geddes, J.R., A. Gardiner, J. Rendell, et al. 2016. Comparative evaluation of quetiapine plus lamotrigine versus quetiapine monotherapy (and folic acid versus placebo) in people with bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 3: 31-39.
30. McIntyre, R.S., J. Cucchiaro, A. Pikalov, et al. 2015. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J. Clin. Psychiatry 76: 398-405.
31. Calabrese, J.R., M.A. Frye, R. Yang, T.A. Ketter ; Armodafinil Treatment Trial Study Network. 2014. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. J. Clin. Psychiatry 75: 1054-1061.
32. Ketter, T.A., R. Yang & M.A. Frye . 2015. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J. Affect. Disord. 181: 87-91.
33. McCloud, T.L., C. Caddy, J. Jochim, et al. 2015. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst. Rev. 9: CD011611.
34. Schoeyen, H.K., U. Kessler, O.A. Andreassen, et al. 2015. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am. J. Psychiatry 172: 41-51.
35. Geddes, J.R., S. Burgess, K. Hawton, et al. 2004. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry 161: 217-222.
36. Geddes, J.R., G.M. Goodwin, J. Rendell ; BALANCE Investigators. 2010. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375: 385-395.
37. Cipriani, A., C. Barbui, J. Rendell & J.R. Geddes . 2014. Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. Acta Psychiatr. Scand. 129: 328-342.
38. Miura, T., H. Noma, T.A. Furukawa, et al. 2014. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1: 351-359.
39. Miziou, S., E. Tsitsipa, S. Moysidou, et al. 2015. Psychosocial treatment and interventions for bipolar disorder: a systematic review. Ann. Gen. Psychiatry 14: 19.
40. McKnight, R.F., M. Adida, K. Budge, et al. 2012. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379: 721-728.
41. Close, H., J. Reilly, J.M. Mason, et al. 2014. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS One 26: e90169.
42. Clos, S., P. Rauchhaus, A. Severn, et al. 2015. Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-based cohort study. Lancet Psychiatry 2: 1075-1083.
43. Kessing, L.V., T.A. Gerds, B. Feldt-Rasmussen, et al. 2015. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiatry 72: 1182-1191.
44. Shine, B., R.F. McKnight, L. Leaver & J.R. Geddes . 2015. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386: 461-468.
45. Wesseloo, R., A.M. Kamperman, T. Munk-Olsen, et al. 2016. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am. J. Psychiatry 173: 117-127.
46. Diav-Citrin, O., S. Schechtman, E. Tahover, et al. 2014. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am. J. Psychiatry 171: 785-794.
47. Bergink, V. & S.A. Kushner . 2014. Lithium during pregnancy. Am. J. Psychiatry 171: 712-715.
48. Bodén, R., M. Lundgren, L. Brandt, et al. 2012. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. Br. Med. J. 345: e7085.
49. Cipriani, A., K. Hawton, S. Stockton & J.R. Geddes . 2013. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346: f3646.
50. Gerhard, T., D.P. Devenand, C. Huang, et al. 2015. Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br. J. Psychiatry 207: 46-51.
51. Lan, C.C., C.C. Liu, C.J. Lin, et al. 2015. A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study. Bipolar Disord. 17: 705-714.
52. Smith, E.G., K.L. Austin, H.M. Kim, et al. 2015. Mortality associated with lithium and valproate treatment of US Veterans Administration patients with mental disorders. Br. J. Psychiatry 207: 55-63.
53. Davis, J.M., A. Rosenbaum, V. Shahinian & F.C. Brosius . 2015. Prevention of lithium-associated renal failure: recent evidence. Lancet Psychiatry 2: 1045-1047.
54. Goodwin, G.M. 2015. The safety of lithium. JAMA Psychiatry 72: 1167-1169.
55. Moore, J.L. & P. Aggarwal . 2012. Lamotrigine use in pregnancy. Exp. Opin. Pharmacother. 13: 1213-1216.
56. Correll, C., J. Detraux, J. De Lepeliere & M. De Hert . 2015. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14: 119-136.
57. Tanoshima, M., T. Kobayashi, R. Tanoshima, et al. 2015. Risks of congenital malformations in offspring exposed to valproic acid in utero: a systematic review and cumulative meta-analysis. Clin. Pharmacol. Ther. 98: 417-441.
58. Alda, M. 2015. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol. Psychiatry 20: 661-670.
59. Berridge, M.J. 2014. Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia. Cell Tissue Res. 357: 477-492.
60. + channels by lithium. Proc. Natl. Acad. Sci. U.S.A. 111: 5018-5023.
61. Hou, L., U. Heilbronner, F. Degenhardt, et al. 2016. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. doi: 10.1016/S0140-6736(16)00143-4.
62. Singh, N., A.C. Halliday, J.M. Thomas, et al. 2013. A safe lithium mimetic for bipolar disorder. Nat. Commun. 4: 1332.
63. Singh, N., A.L. Sharpley, U.E. Emir, et al. 2016. Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans. Neuropsychopharmacology. doi: 10.1038/npp.2015.343.
64. Schloesser, R.J., K. Martinowich & H.K. Manji . 2012. Mood-stabilizing drugs: mechanisms of action. Trends Neurosci. 35: 36-46.
65. Chiu, C.T., Z. Wang, J.G. Hunsberger & D.M. Chuang . 2013. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol. Rev. 65: 105-142.
66. Brodie, M.J. 1992. Lamotrigine. Lancet 339: 1397-1400.
67. Ketter, T.A., H.K. Manji & R.M. Post . 2003. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J. Clin. Psychopharmacol. 23: 484-495.
68. Goodwin, G.M. & J.R. Geddes . 2007. What is the heartland of psychiatry? Br. J. Psychiatry 191: 189-191.
69. Nutt, D. & G. Goodwin . 2011. ECNP summit on the future of CNS drug research in Europe 2011. Eur. Neuropsychopharmacol. 21: 495-499.
70. Paykel, E.S., R. Abbott, R. Morriss, et al. 2006. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br. J. Psychiatry 189: 118-123.
71. Bauer, M., T. Glenn, P. Grof, et al. 2010. Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder. Psychopathology 43: 1-7.
72. Rush, A.J., M.H. Trivedi, H.M. Ibrahim, et al. 2003. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54: 573-583.
73. Bilderbeck, A.C., K.E.A. Saunders, G.D. Clifford, et al. 2015. Daily and weekly mood ratings: relative contributions to the differentiation of bipolar disorder and borderline personality disorder. Bipolar Disord. 17(Suppl. 1): 129-130.
74. Saunders, K.E.A., A. Cipriani, J. Rendell, et al. 2016. Oxford lithium trial (OxLith) of the early affective, cognitive, neural, biochemical effects of lithium carbonate in bipolar disorder: study protocol for a randomised controlled trial. Trials 17: 116.
75. Glenn, T. & S. Monteith . 2014. New measures of mental state and behavior based on data collected from sensors, smartphones, and the Internet. Curr. Psychiatry Rep. 16: 523.
76. Faurholt-Jepsen, M., M. Frost, C. Ritz, et al. 2015. Daily electronic self-monitoring in bipolar disorder using smartphones-the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial. Psychol. Med. 45: 2691-2704.
77. Hidalgo-Mazzei, D., A. Mateu, M. Reinares, et al. 2015. Self-monitoring and psychoeducation in bipolar patients with a smart-phone application (SIMPLe) project: design, development and studies protocols. BMC Psychiatry 15: 52.
78. Nicholas, J., M.E. Larsen, J. Proudfoot & H. Christensen . 2015. Mobile apps for bipolar disorder: a systematic review of features and content quality. J. Med. Internet Res. 17: e198.
79. Tourus, J. & A.C. Powell . 2015. Current research and trends in the use of smartphone applications for mood disorders. Internet Interv. 2: 169-173.
80. Faurholt-Jepsen, M., K. Munkholm, M. Frost, et al. 2016. Electronic self-monitoring of mood using IT platforms in adult patients with bipolar disorder: a systematic review of the validity and evidence. BMC Psychiatry 16: 7.
81. Onnela, J.-P. & S.L. Rauch . 2016. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology. doi: 10.1038/npp.2016.7.
82. Schwartz, S., S. Schultz, A. Reider & E.F.H. Saunders . 2016. Daily mood monitoring of symptoms using smartphones in bipolar disorder: a pilot study assessing the feasibility of ecological momentary assessment. J. Affect. Disord. 191: 88-93.
83. Saunders, K.E.A., A.C. Bilderbeck, P. Panchal, et al. 2015. Acceptability and tolerability of ambulatory monitoring in bipolar disorder: a patient perspective. Bipolar Disord. 17(Suppl. 1): 86.
84. Henry, C., D. Van den Bulke, F. Bellivier, et al. 2008. Affective lability and affect intensity as core dimensions of bipolar disorders during euthymic period. Psychiatry Res. 159: 1-6.
85. Ortiz, A., K. Bradler, J. Garnham, et al. 2015. Nonlinear dynamics of mood regulation in bipolar disorder. Bipolar Disord. 17: 139-149.
86. Bonsall, M.B., S.M. Wallace-Hadrill, J.R. Geddes, et al. 2012. Nonlinear time-series approaches in characterizing mood stability and mood instability in bipolar disorder. Proc. Biol. Sci. 279: 916-924.
87. Moore, P.J., M.A. Little, P.E. McSharry, et al. 2014. Mood dynamics in bipolar disorder. Int. J. Bipolar Disord. 2: 11.
88. Bonsall, M.B., J.R. Geddes, E.A. Holmes & G.M. Goodwin . 2015. Bipolar disorder dynamics: affective instabilities, relaxation oscillations and noise. J. R. Soc. Interface 12: 20150670.
89. Birmaher, B., B.I. Goldstein, D.A. Axelson, et al. 2013. Mood lability among offspring of parents with bipolar disorder and community controls. Bipolar Disord. 15: 253-263.
90. Hafeman, D.M., J. Merranko, D. Axelson, et al. 2016. Toward the definition of a bipolar prodrome: dimensional predictors of bipolar spectrum disorders in at-risk youths. Am. J. Psychiatry. doi: 10.1176/appi.ajp.2015.15040414.
91. Howes, O.D., S. Lim, G. Theologos, et al. 2011. A comprehensive review and model of putative prodromal features of bipolar affective disorder. Psychol. Med. 41: 1567-1577.
92. Patel, R., T. Lloyd, R. Jackson, et al. 2015. Mood instability is a common feature of mental health disorders and is associated with poor clinical outcomes. BMJ Open 5: e007504.
93. Strejilevich, S.A., D.J. Martino, A. Murru, et al. 2013. Mood instability and functional recovery in bipolar disorders. Acta Psychiatr. Scand. 128: 194-202.
94. Gershon, A. & P. Eidelman . 2015. Inter-episode affective intensity and instability: predictors of depression and functional impairment in bipolar disorder. J. Behav. Ther. Exp. Psychiatry 46: 14-18.
95. Solhan, M.B., T.J. Trull, S. Jahng & P.K. Wood . 2009. Clinical assessment of affective instability: comparing EMA indices, questionnaire reports, and retrospective recall. Psychol. Assess. 21: 425-436.
96. Marwaha, S., Z. He, M. Broome, et al. 2014. How is affective instability defined and measured? A systematic review. Psychol. Med. 44: 1793-1808.
97. Broome, M.R., Z. He, M. Iftikhar, et al. 2015. Neurobiological and behavioural studies of affective instability in clinical populations: a systematic review. Neurosci. Biobehav. Rev. 51: 243-254.
98. Beckmann, C.F., M. DeLuca, J.T. Devlin & S.M. Smith . 2005. Investigations into resting-state connectivity using independent component analysis. Phil. Trans. R. Soc. Lond. B Biol. Sci. 360: 1001-1013.
99. Smith, S.M., K.L. Miller, S. Moeller, et al. 2012. Temporally-independent functional modes of spontaneous brain activity. Proc. Natl. Acad. Sci. U.S.A. 109: 3131-3136.
100. Proudfoot, M., M.W. Woolrich, A.C. Nobre & M.R. Turner . 2014. Magnetoencephalography. Pract. Neurol. 14: 336-343.
101. Brookes, M.J., M. Woolrich, H. Luckhoo, et al. 2011. Investigating the electrophysiological basis of resting state networks using magnetoencephalography. Proc. Natl. Acad. Sci. U.S.A. 108: 16783-16788.
102. Luckhoo, H., J.R. Hale, M.G. Stokes, et al. 2012. Inferring task-related networks using independent component analysis in magnetoencephalography. Neuroimage 62: 530-541.
103. Baker, A.P., M.J. Brookes, I.A. Rezek, et al. 2014. Fast transient networks in spontaneous human brain activity. eLife 3: e01867.
104. Harmer, C.J., P.J. Cowen & G.M. Goodwin . 2011. Efficacy markers in depression. J. Psychopharmacol. 25: 1148-1158.
105. Warren, M.B., A. Pringle & C.J. Harmer . 2015. A neurocognitive model for understanding treatment action in depression. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370: 20140213.
106. Phillips, M.L. & H.A. Swartz . 2014. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am. J. Psychiatry 171: 829-843.
107. Craddock, N. & P. Sklar . 2013. Genetics of bipolar disorder. Lancet 381: 1654-1662.
108. Shinozaki, G. & J.B. Potash . 2014. New developments in the genetics of bipolar disorder. Curr. Psychiatry Rep. 16: 493.
109. Mühleisen, T.W., M. Leber, T.G. Schulze, et al. 2014. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat. Commun. 11: 3339.
110. Green, E.K., E. Rees, J.T.R. Walters, et al. 2016. Copy number variation in bipolar disorder. Mol. Psychiatry 21: 89-93.
111. Hasler, G. & A. Wolf . 2015. Toward stratified treatments for bipolar disorders. Eur. Neuropsychopharmacol. 25: 283-294.
112. Plenge, R.M., E.M. Scolnick & D. Altshuler . 2013. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12: 581-594.
113. Harrison, P.J. 2015. Recent genetic findings in schizophrenia and their therapeutic relevance. J. Psychopharmacol. 29: 85-96.
114. Nelson, M.R., H. Tipney, J.L. Painter, et al. 2015. The support of human genetic evidence for approved drug indications. Nat. Genet. 47: 856-860.
115. Papassotiropoulos, A. & D.J. de Quervain . 2015. Failed drug discovery in psychiatry: time for human genome-guided solutions. Trends Cogn. Sci. 19: 183-187.
116. Harrison, P.J. 2016. Molecular neurobiological clues to the pathogenesis of bipolar disorder. Curr. Opin. Neurobiol. 36: 1-6.
117. Warsh, J.J., S. Andreopoulos & P.P. Li . 2004. Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status. Clin. Neurosci. Res. 4: 201-213.
118. v1.2) in the pathophysiology of psychiatric disease. Prog. Neurobiol. 99: 1-14.
119. McCarthy, M.J., M.J. Le Roux, H. Wei, et al. 2016. Calcium channel genes associated with bipolar disorder modulate lithium's amplification of circadian rhythms. Neuropharmacology 101: 439-448.
120. Ament, S.A., S. Szelinger, G. Glusman, et al. 2015. Rare variants in neuronal excitability genes influence risk for bipolar disorder. Proc. Natl. Acad. Sci. U.S.A. 112: 3576-3581.
121. Levy, N.A. & P.G. Janicak . 2000. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord. 2: 108-119.
122. Cipriani, A., K. Saunders, M.-J. Attenburrow, et al. 2016. Calcium channel antagonists in bipolar disorder. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol. Psychiatry. In press.
123. Ostacher, M.J., D.V. Iosifescu, A. Hay, et al. 2014. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. Bipolar Disord. 2: 199-203.
124. 2+ channels in heart and brain. Wiley Interdiscip. Rev. Membr. Transp. Signal. 3: 15-38.
125. Hopkins, A.L. & C.R. Groom . 2002. The druggable genome. Nat. Rev. Drug Discov. 1: 727-730.
126. Rasband, M.N. 2010. The axon initial segment and the maintenance of neuronal polarity. Nat. Rev. Neurosci. 11: 552-562.
127. Smith, K.R., K.J. Kopeikina, J.M. Fawcett-Patel, et al. 2014. Psychiatric risk factor ANK3/ankyrin-G nanodomains regulate the structure and function of glutamatergic synapses. Neuron 84: 399-415.
128. Durak, O., F.C. de Anda, K.K. Singh, et al. 2015. Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of β-catenin. Mol. Psychiatry 20: 388-397.
129. Rueckert, E.H., D. Barker, D. Ruderfer, et al. 2013. Cis-acting regulation of brain-specific ANK3 gene expression by a genetic variant associated with bipolar disorder. Mol. Psychiatry 18: 922-929.
130. Cross-Disorder Group of the Psychiatric Genomics Consortium. 2013. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381: 1371-1379.
131. A receptors on a component of the bipolar disorder phenotype. Mol. Psychiatry 15: 146-153.
132. Goes, F.S., M.L. Hamshere, F. Seifuddin, et al.; Bipolar Genome Study (BIGS). 2012. Genome-wide association of mood-incongruent psychotic bipolar disorder. Transl. Psychiatry 2: e180.
133. Greenwood, T.A., Bipolar Genome Study (BiGS) Consortium & J.R. Kelsoe . 2013. Genome-wide association study of irritable vs. elated mania suggests genetic differences between clinical subtypes of bipolar disorder. PLoS One 8: e53804.
134. Insel, T., B. Cuthbert, M. Garvey, et al. 2010. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167: 748-751.
135. Lee, R.S., D.F. Hermens, J. Scott, et al. 2014. A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. J. Psychiatr. Res. 57: 1-11.
136. Martinez-Aran, A. & E. Vieta . 2015. Cognition as a target in schizophrenia, bipolar disorder and depression. Eur. Neuropsychopharmacol. 25: 151-157.
137. Harvey, A.G. 2008. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am. J. Psychiatry 165: 820-829.
138. Levenson, J.C., D.A. Axelson, J. Merranko, et al. 2015. Differences in sleep disturbances among offspring of parents with and without bipolar disorder: association with conversion to bipolar disorder. Bipolar Disord. 17: 836-848.
139. Ritter, P.S., M. Höfler, H.U. Wittchen, et al. 2015. Disturbed sleep as risk factor for the subsequent onset of bipolar disorder-data from a 10-year prospective-longitudinal study among adolescents and young adults. J. Psychiatr. Res. 68: 76-82.
140. Cretu, J.B., J.L. Culver, K.C. Goffin, et al. 2016. Sleep, residual symptoms, and time to relapse in recovered patients with bipolar disorder. J. Affect. Disord. 190: 162-166.
141. Pinho, M., M. Sehmbi, L. Cudney, et al. 2016. The association between biological rhythms, depression, and functioning in bipolar disorder: a large multi-center study. Acta Psychiatr. Scand. 133: 102-108.
142. Byrne, E.M., P.R. Gehrman, S.E. Medland, et al.; Chronogen Consortium. 2013. A genome-wide association study of sleep habits and insomnia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B: 439-451.
143. Parsons, M.J., K.J. Lester, N.L. Barclay, et al. 2013. Replication of genome-wide association studies (GWAS) loci for sleep in the British G1219 cohort. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B: 431-438.
144. Heck, A., M. Fastenrath, S. Ackermann, et al. 2014. Converging genetic and functional brain imaging evidence links neuronal excitability to working memory, psychiatric disease, and brain activity. Neuron 81: 1203-1213.
145. Heck, A., M. Fastenrath, D. Coynel, et al. 2015. Genetic analysis of association between calcium signaling and hippocampal activation, memory performance in the young and old, and risk for sporadic Alzheimer disease. JAMA Psychiatry 72: 1029-1036.
146. Viswanath, B., S.P. Jose, A. Squassina, et al. 2015. Cellular models to study bipolar disorder: a systematic review. J. Affect. Disord. 15: 36-50.
147. Andreazza, A.C. & L.T. Young . 2015. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int. J. Neuropsychopharmacol. 17: 1039-1052.
148. Chen, H.M., C.J. DeLong, M. Bame, et al. 2014. Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients. Transl. Psychiatry 4: e375.
149. Wang, J.L., S.M. Shamah, A.X. Sun, et al. 2014. Label-free, live optical imaging of reprogrammed bipolar disorder patient-derived cells reveals a functional correlate of lithium responsiveness. Transl. Psychiatry 4: e428.
150. Madison, J.M., F. Zhou, A. Nigam, et al. 2015. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. Mol. Psychiatry 20: 703-717.
151. Mertens, J., Q.-W. Wang, Y. Kim, et al.; Pharmacogenomics of Bipolar Disorder Study. 2015. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature 527: 95-99.
152. Yoshimizu, T., J.Q. Pan, A.E. Mungenast, et al. 2015. Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Mol. Psychiatry 20: 162-169.
153. Bigos, K.L., V.S. Mattay, J.H. Callicott, et al. 2010. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch. Gen. Psychiatry 67: 939-945.
154. Malhi, G.S. & J.R. Geddes . 2014. Carving bipolarity using a lithium sword. Br. J. Psychiatry 205: 337-339.
155. Tighe, S.K., P.B. Mahon & J.B. Potash . 2011. Predictors of lithium response in bipolar disorder. Ther. Adv. Chronic Dis. 2: 209-226.
156. Harrison, P.J., M.Z. Cader & J.R. Geddes . 2016. Reprogramming psychiatry: stem cells and bipolar disorder. Lancet 387: 823-825.
157. Kaiser, T. & G. Feng . 2015. Modeling psychiatric disorders for developing effective treatments. Nat. Med. 21: 979-988.
158. Einat, H. 2007. Different behaviors and different strains: potential new ways to model bipolar disorder. Neurosci. Biobehav. Rev. 31: 850-857.
159. Cosgrove, V.E., J.R. Kelsoe & T. Suppes . 2016. Toward a valid animal model of bipolar disorder: how the research domain criteria help bridge the clinical-basic science divide. Biol. Psychiatry 79: 62-70.
160. Han, K., J.L. Holder, C.P. Schaaf, et al. 2013. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 503: 72-77.
161. Leussis, M.P., E.M. Berry-Scott, M. Saito, et al. 2013. The ANK3 bipolar disorder gene regulates psychiatric-related behaviors that are modulated by lithium and stress. Biol. Psychiatry 73: 683-690.
162. Sidor, M.M., S.M. Spencer, K. Dzirasa, et al. 2015. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol. Psychiatry 20: 1406-1419.
163. Chung, S., E.J. Lee, S. Yun, et al. 2014. Impact of circadian nuclear receptor REV-ERBα on midbrain dopamine production and mood regulation. Cell 157: 858-868.
164. McClung, C.A. 2011. Circadian rhythms and mood regulation: insights from pre-clinical models. Eur. Neuropsychopharmacol. 21(Suppl. 4): S683-S693.